"Manufacturers Warn of Challenges in Reformulating Flu Vaccine"
Originally Published 2 years ago — by STAT
The World Health Organization and drug regulators are urging flu vaccine manufacturers to remove the B/Yamagata component from flu vaccines due to its apparent eradication during the Covid-19 pandemic. However, the process is complex and may take until the 2025-2026 Northern Hemisphere cycle to be implemented globally, with over 350 trivalent vaccine licenses needing updates and approvals from approximately 170 regulatory agencies. The International Federation of Pharmaceutical Manufacturers and Associations is advocating for a synchronized global shift, while some experts believe the transition can be made sooner in certain countries.